Avalo Therapeutics
AVTX----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Avalo Therapeutics(AVTX) predict that the EBIT is -20.9 M (-42.48%), Miss estimate;the EPS is -0.98 (+21.6%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B42.48%
-0.02B34.60%
-0.00B7.88%
EPSExceed expectations
-0.9821.60%
-1.025617.96%
+0.04563.64%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf